A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression - Test2 - elhamkhani - TriplyDB

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

http://www.wikidata.org/entity/Q24630153

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder Rapid antidepressant effects: moving right along Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders To use or not to use: an update on licit and illicit ketamine use Ketamine enantiomers in the rapid and sustained antidepressant effects Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants Pharmacological Approaches for Treatment-resistant Bipolar Disorder Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders Antidepressant mechanism of ketamine: perspective from preclinical studies Ketamine, sleep, and depression: current status and new questions Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Review of pharmacological treatment in mood disorders and future directions for drug development.A review of MR spectroscopy studies of pediatric bipolar disorder Antidepressant actions of ketamine: from molecular mechanisms to clinical practice Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Cell atrophy and loss in depression: reversal by antidepressant treatment Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy A brief history of the development of antidepressant drugs: from monoamines to glutamate Restoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice.Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions.The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm Ketamine: 50 Years of Modulating the Mind Emergent treatments based on the pathophysiology of bipolar disorder: A selective review R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression Treatment of bipolar disorder Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice Innovative solutions to novel drug development in mental health Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment Options for Pharmacological Treatment of Refractory Bipolar Depression Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study.NMDAR inhibition-independent antidepressant actions of ketamine metabolites.Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.Acute D-serine treatment produces antidepressant-like effects in rodents Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.

P2860

Q21129276-360AC1D8-4AC5-43A9-9861-E130C478D842 Q22252957-2BF0B20D-7831-4AEF-A239-34CD7B7E5560 Q24602988-F2BA1665-05CC-4F91-BF6E-5667910AA452 Q24614410-3FF04843-1A1E-4163-A9EA-F86BD851BA33 Q24629398-1B96E91B-97B3-40C4-A6AB-790EF4A56982 Q24632936-12A094A7-DBAA-4626-8AAF-220A0976884E Q24634006-DDC20FE0-5159-4D0F-87C5-E90B63FB0B9F Q26746141-01004471-852C-47FD-A794-9B189BF8B912 Q26750021-B98CCDE7-07A1-4F1E-9DD0-82374DD47282 Q26782274-C71ABF11-A84B-4A8E-86EC-ED71DF465784 Q26783002-AB6BD48F-E8E5-494A-8B96-6B650BF084BF Q26784904-C9A14828-FC0A-44B3-A54F-EE65D8ABC822 Q26800231-79706234-D60B-4603-920F-C5AACE2E18A9 Q26828564-FFAF8CFA-61CF-422E-9E2D-FBF1616563E5 Q26829556-4F74B1CA-021D-44E0-936A-703C3B9DE41A Q26853509-0405CE54-8378-45E0-81FF-B0AE14147922 Q26991430-248A523F-5792-4031-AC5A-7BD7A7130E58 Q26995879-CEB09C95-F424-4523-828D-83CD3BADEDCB Q27004490-84E12EFB-C856-427C-9264-D2DD4A529D1B Q27013609-08AF1FA9-DBA0-4066-A503-3DD1767D6CA8 Q27024227-7B4040D0-95EF-46B1-A660-34BC98A54D00 Q27028050-C8359F13-2AF5-42DF-AC47-8664AF4DAD25 Q27300750-9F405CDA-82D8-4D0C-B9E4-73AD9DF633DA Q27328579-21818251-EC5F-4FD7-9560-8F648C7CA02B Q28066714-C3353806-57FC-48D2-B858-6DC14C426040 Q28077524-5F629CA4-798C-4FD4-B783-4B0905BA9DB2 Q28082445-333266E8-BD4C-4904-8CE5-D33FF69C95CC Q28266846-3B34E75E-0E10-4626-A342-37976CEC6649 Q28277636-51DB1134-A6D9-474E-9F5D-8BFE21ACD63B Q28290437-9109C85C-BDFA-4DD8-AD2C-14B520B2E3AE Q28485938-DFFFCC16-CF52-45AE-BCCF-027524CEFCCC Q28677399-F5EAFBD9-92E2-4589-81D9-99CEA0D155AB Q28729135-287C4597-7F26-436E-A924-5DE2A8D17720 Q29395337-1C5EA6C8-4A03-4A8C-8932-38A9989AC452 Q30359978-823817F8-5E02-4E6F-BAA4-802CBC869335 Q30370600-64B498BA-A416-46CE-AE31-37C7097543DD Q30423149-D7662E95-B300-41A2-889C-E1E0AECAEC6E Q30440925-C8106B37-29D9-4CF2-A041-CAD180C98B67 Q30505292-412676CE-B62C-4341-9E47-C9BD4BF3A762 Q30547324-2FB9ACCD-D9ED-4C9F-B501-7B4271359781

P2860

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

http://www.wikidata.org/entity/Q24630153

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A randomized add-on trial of a ...... t-resistant bipolar depression

@ast

A randomized add-on trial of a ...... t-resistant bipolar depression

@en

A randomized add-on trial of a ...... t-resistant bipolar depression

@nl

type

label

A randomized add-on trial of a ...... t-resistant bipolar depression

@ast

A randomized add-on trial of a ...... t-resistant bipolar depression

@en

A randomized add-on trial of a ...... t-resistant bipolar depression

@nl

prefLabel

A randomized add-on trial of a ...... t-resistant bipolar depression

@ast

A randomized add-on trial of a ...... t-resistant bipolar depression

@en

A randomized add-on trial of a ...... t-resistant bipolar depression

@nl

P1433

Q24630153-18099540-2240-40EB-878A-C9C80B6349AA

P1476

Q24630153-83932663-29E1-402C-ACE2-1948A1B292C2

P2093

Q24630153-1500A0E8-D8A1-4914-BADD-38AF06018FFD

Q24630153-362DCADA-B317-49B5-9B03-673747EA7A68

Q24630153-486F355F-0B6D-4AF4-B7DD-A8C01FACB0D0

Q24630153-602D7FD8-3DF3-48D4-8E26-9E2F2F34F3AF

Q24630153-7C91507E-AC56-4B58-81CF-3DA6D2D8A80C

Q24630153-937A18D7-EE4B-4EA4-B0ED-4A442BA9B3AE

Q24630153-99303E6E-4C25-473E-8EAB-0075063B3205

Q24630153-A431C135-49FA-4FA8-A4BC-9831F5CA5247

Q24630153-B2B829B8-2C3F-44D5-974B-30FB71DF0D0C

Q24630153-EBB0F0E0-34BA-46EF-8A26-665827CCFDE2

P2860

Q24630153-03B8AB5B-8FA5-48B1-AA20-2A2C7326C0C2

Q24630153-053A0EBE-E718-4C5E-85CC-E23F239741F1

Q24630153-076A05FC-AB6E-4170-BD15-32E8BFE0CA3B

Q24630153-1830AEDE-08B2-44A2-9BAD-F5362608A5E2

Q24630153-1D4B38D2-555A-477D-A6AF-A7FB8E36837B

Q24630153-24CC61D2-FEFB-4754-B531-CCC566CD087F

Q24630153-26795954-59F3-4A6F-9D16-D9B4E8727241

Q24630153-26F3B8B6-83E7-4C82-9376-974916F50F47

Q24630153-3AD31FED-3F0B-4C23-9DF8-8624B7A2C51B

Q24630153-3BAA0E4B-D60C-4D43-9FBA-4957101FB10D

P304

Q24630153-CDE68A8D-0A14-4F8E-8386-61A3FB914D3A

P31

Q24630153-195420E2-8545-49D0-ACFB-908A832129EB

P3181

Q24630153-4CC4C484-5DA0-4B2F-8ADA-6DC55083C446

P356

Q24630153-81684D4C-73C3-4C14-862E-758B93D19B44

P407

Q24630153-356A7FA5-97B8-4AAC-9420-12CBC14BCCF9

P433

Q24630153-DF60CD38-1D7D-457C-B4B5-DE8D06A04AEE

P478

Q24630153-AAA72BDA-F5B6-4E08-8E84-18B6DC970E4B

P50

Q24630153-19A2DD9A-5260-4D5E-A62F-97B05C13F139

Q24630153-6894DBCD-447B-421E-8FAB-499283FF365B

Q24630153-FB156E0F-4A3A-4850-986B-6DD03C1265D0

P577

Q24630153-067E1FC5-BD14-49C5-977C-7D19A0DD29F8

P5875

Q24630153-54451845-0143-41B2-ABD7-A69F9D8E2689

P698

Q24630153-0932AC9A-3C80-47ED-9859-3950D1794421

P932

Q24630153-72B89396-CCBF-4707-B113-8A989065A425

P3181

P356

ARCHGENPSYCHIATRY.2010.90

P1433

JAMA Psychiatry

P1476

A randomized add-on trial of a ...... t-resistant bipolar depression

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

David A Luckenbaugh

http://www.w3.org/2001/XMLSchema#string

Giacomo Salvadore

http://www.w3.org/2001/XMLSchema#string

Husseini K Manji

http://www.w3.org/2001/XMLSchema#string

Lobna Ibrahim

http://www.w3.org/2001/XMLSchema#string

Nancy Diazgranados

http://www.w3.org/2001/XMLSchema#string

Nancy E Brutsche

http://www.w3.org/2001/XMLSchema#string

Phillip Kronstein

http://www.w3.org/2001/XMLSchema#string

Sami Khalife

http://www.w3.org/2001/XMLSchema#string

William A Kammerer

http://www.w3.org/2001/XMLSchema#string

P2860

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication

A rating scale for depression

Effectiveness of adjunctive antidepressant treatment for bipolar depression

Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys

The assessment of anxiety states by rating

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

A rating scale for mania: reliability, validity and sensitivity

Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

P304

793-802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2232706

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/ARCHGENPSYCHIATRY.2010.90

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Zenaide Quezado

Andrew B. Newberg

Rodrigo Machado-Vieira

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45461726

http://www.w3.org/2001/XMLSchema#string

P698

20679587

http://www.w3.org/2001/XMLSchema#string

P932

3000408

http://www.w3.org/2001/XMLSchema#string